Institution
Mitsubishi
Company•Tokyo, Japan•
About: Mitsubishi is a company organization based out in Tokyo, Japan. It is known for research contribution in the topics: Signal & Layer (electronics). The organization has 53115 authors who have published 54821 publications receiving 870150 citations. The organization is also known as: Mitsubishi Group of Companies & Mitsubishi Companies.
Topics: Signal, Layer (electronics), Semiconductor memory, Electrode, Voltage
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This paper designs, implemented, and studied a variety of tabletop user interfaces, interaction techniques, and usage scenarios, including the need for input methods that transcend traditional mouse- and keyboard-based designs.
Abstract: Tables provide a large and natural interface for supporting direct manipulation of visual content for human-to-human interactions. Such surfaces also support collaboration, coordination, and parallel problem solving. However, the direct-touch table metaphor also presents considerable challenges, including the need for input methods that transcend traditional mouse- and keyboard-based designs. In this paper, we've designed, implemented, and studied a variety of tabletop user interfaces, interaction techniques, and usage scenarios
159 citations
••
TL;DR: There is an evolving trend towards increased resistance to clarithromycin with geographical and gender differences as well as between clinical disease conditions in Japan, and current empirical regimens are not based on susceptibility data representative of the general population.
Abstract: Surveillance of Helicobacter pylori antimicrobial susceptibility reflecting the general population in Japan is limited. The antimicrobial susceptibilities of 3,707 H. pylori strains isolated from gastric mucosa samples of previously untreated patients diagnosed with gastroduodenal diseases at 36 medical facilities located throughout Japan between October 2002 and September 2005 were evaluated. Using an agar dilution method for antimicrobial susceptibility testing of H. pylori, the MIC distributions and trends during the study period for clarithromycin, amoxicillin, and metronidazole were studied. While the MIC50 and MIC90 for clarithromycin did not change during the 3-year period, the MIC80 showed a 128-fold increase. Furthermore, the rate of resistance increased yearly from 18.9% (2002 to 2003) to 21.1% (2003 to 2004) and 27.7% (2004 to 2005). With a resistance rate of 19.2% among males compared to 27.0% among females, a significant gender difference was observed (P < 0.0001). Our study shows that in Japan, there is an evolving trend towards increased resistance to clarithromycin with geographical and gender differences as well as between clinical disease conditions. No significant changes in resistance were observed for amoxicillin and metronidazole during the period. While the benefit of H. pylori antimicrobial susceptibility testing has been debated in Japan, current empirical regimens are not based on susceptibility data representative of the general population. The development of an effective H. pylori eradication regimen in Japan will require continued resistance surveillance as well as a better understanding of the epidemiology of resistance.
159 citations
••
TL;DR: Results suggest that, despite the identical composition of tau isoforms, different proteolytic processing of abnormal tau takes place in these two diseases, and such a biochemical divergence may be related to the neuropathological features of these diseases.
Abstract: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative diseases that are characterized by intracytoplasmic aggregates of hyperphosphorylated tau with four microtubule-binding repeats. Although PSP and CBD have distinctive pathological features, no biochemical difference in aggregated tau has been identified. In this study, we examined the brains of eight patients with PSP, six patients with CBD, and one atypical case with pathological features of both CBD and PSP. On immunoblots of sarkosyl-insoluble brain extracts, a 33kDa band predominated in the low molecular weight tau fragments in PSP, whereas two closely related bands of approximately 37kDa predominated in CBD. Immunoblots of the atypical case showed both the 33kDa band and the 37kDa doublet. Protein sequencing and immunochemical analyses showed that the 33kDa band and the 37kDa doublet consisted of the carboxyl half of tau with different amino termini. These results suggest that, despite the identical composition of tau isoforms, different proteolytic processing of abnormal tau takes place in these two diseases. Such a biochemical divergence may be related to the neuropathological features of these diseases.
158 citations
••
TL;DR: The results suggest that MCI-186 attenuates brain edema by suppressing the production of lipoxygenase metabolites, including free radicals or lipid peroxides, and that it may prove valuable for the treatment ofbrain edema associated with cerebral ischemia.
Abstract: We induced brain edema in 72 rats by injecting 5 microliters of 3.0% wt:vol polyvinyl acetate into the left internal carotid artery, producing permanent embolization in the left cerebral hemisphere, which developed ipsilateral brain edema reproducibly. Edema was assessed 24 hours after embolization by determining the brain water content and the sodium and potassium concentrations. In this model, the free radical scavenger MCI-186 at 1.0 and 3.0 mg/kg i.v. prevented brain edema in a dose-dependent manner. At 3.0 mg/kg i.v., MCI-186 significantly reduced water content by 1.5% and improved the sodium-potassium balance to within the normal range in the embolized left hemisphere. Dexamethasone at 1.0 mg/kg i.v. did but at 3.0 mg/kg i.v. did not significantly inhibit the development of brain edema. Indomethacin at 4.0 mg/kg i.p. had no effect on brain edema. We suggest that the cyclooxygenase metabolites of arachidonic acid liberated from neuronal cell membrane phospholipids are not likely to be involved in the pathogenesis of permanent brain edema induced by polyvinyl acetate. Our results suggest that MCI-186 attenuates brain edema by suppressing the production of lipoxygenase metabolites, including free radicals or lipid peroxides, and that it may prove valuable for the treatment of brain edema associated with cerebral ischemia.
158 citations
••
TL;DR: A novel glycosphingolipid-degrading enzyme was found in the cultured supernatant of Rhodococcus sp.
158 citations
Authors
Showing all 53117 results
Name | H-index | Papers | Citations |
---|---|---|---|
Thomas S. Huang | 146 | 1299 | 101564 |
Kazunari Domen | 130 | 908 | 77964 |
Kozo Kaibuchi | 129 | 493 | 60461 |
Yoshimi Takai | 122 | 680 | 61478 |
William T. Freeman | 113 | 432 | 69007 |
Tadayuki Takahashi | 112 | 932 | 57501 |
Takashi Saito | 112 | 1041 | 52937 |
H. Vincent Poor | 109 | 2116 | 67723 |
Qi Tian | 96 | 1030 | 41010 |
Andreas F. Molisch | 96 | 777 | 47530 |
Takeshi Sakurai | 95 | 492 | 43221 |
Akira Kikuchi | 93 | 412 | 28893 |
Markus Gross | 91 | 588 | 32881 |
Eiichi Nakamura | 90 | 845 | 31632 |
Michael Wooldridge | 87 | 543 | 50675 |